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Abstract The precise function of C-reactive protein (CRP) as a regulator of inﬂammation in health and disease
continues to evolve. The true understanding of its role in host defense responses has been hampered by
numerous reports of comparable systems with contradictory interpretations of CRP as a stimulator, sup-
pressor, or benign contributor to such processes. These discrepancies may be explained in part by the
existence of a naturally occurring CRP isoform, termed modiﬁed CRP (i.e., mCRP), that is expressed when
CRP subunits are dissociated into monomeric structures. The free mCRP subunit undergoes a non-prote-
olytic conformational change that has unique solubility, antigenicity, and bioactivity compared to the sub-
units that remain associated in the native, pentameric CRP molecule (i.e., pCRP). As speciﬁc reagents have
been developed to identify and quantify mCRP, it has become apparent that this isoform can be formed
spontaneously in calcium-free solutions. Furthermore, mCRP can be expressed on perturbed cell mem-
branes with as little as 24–48 h incubation in tissue culture. Because mCRP has the same size as pCRP
subunits as evaluated by SDS-PAGE, its presence in a pCRP reagent would not be apparent using this
technique to evaluate purity. Finally, because many antibody reagents purported to be speciﬁc for ‘‘CRP’’
contains some, or substantial speciﬁcity tomCRP, antigen-detection techniques using such reagentsmay fail
to distinguish the speciﬁc CRP isoform detected. All these caveats concerning CRP structures and mea-
surements suggest that the aforementioned contradictory studies may reﬂect to some extent on distinctive
bioactivities of mCRP rather than on pCRP. To provide a reliable, abundant supply of mCRP for separate and
comparable studies, a recombinant proteinwas engineered and expressed in E. coli (i.e., recombinantmCRP
or rmCRP). Synthesized protein was produced as inclusion bodies which proved difﬁcult to solubilize for
puriﬁcation and characterization. Herein, we describe a method using anhydride reagents to effectively
solubilize rmCRP and allow for chromatographic puriﬁcation in high yield and free of contaminating
endotoxin. Furthermore, the puriﬁed rmCRP reagent represents an excellent comparable protein to the
biologically producedmCRP and as a distinctive reagent from pCRP. Deciphering the true function of CRP in
both health and disease requires a knowledge, understanding, and reliable supply of each of its structures so
to deﬁne the distinctive effects of each on the body’s response to tissue damaging events.
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INTRODUCTION
C-reactive protein (CRP) is generally regarded as one of,
if not the pre-eminent protein of the early acute phase
response. Its concentration in serum is a valuable
diagnostic tool as an index of inﬂammatory tissue
damage, rising from a baseline of 1–3 lg/mL to 100 s of
lg/mL within 8*72 h of any stress that affects tissue
integrity (Kushner 1982; Morley and Kushner 1982;
Gewurz et al. 1995; Gabay and Hushner 1999; Black
et al. 2004). As the inﬂammatory response gets
resolved, serum CRP levels quickly return to baseline.
Since its fractional catabolic rate is independent of its
serum concentration and its clearance is independent of
the stage and type of disease that elicit its response, the
exact relevance of blood-borne CRP to the body’s
response to disease remains unknown. Persistently
elevated CRP concentration reﬂects on an increased rate
of hepatic synthesis and release and is generally
regarded as a reliable indicator of low-level chronic
inﬂammation occurring somewhere in the individual
(Macintyre et al. 1982, 1985; Vigushin et al. 1993).
Because of the deﬁnite association of serum CRP
levels and inﬂammation, it has long been perceived as
some kind of regulator of this process. Efforts to pre-
cisely deﬁne its biological role have identiﬁed various
ligands, tissue distribution, effects on cellular and
humoral effector responses, and relevance as a predic-
tive factor for development of diseases (Ridker et al.
1997; Marnell et al. 2005; Ma et al. 2013; DuClos 2013;
Agrawal et al. 2014). Frustratingly, many reports are in
direct contradiction, and a consensus agreement for
CRP’s exact biological role remains elusive (Paul et al.
2004; Hirschﬁeld et al. 2005; Kovacs et al. 2007;
Teupser et al. 2011).
Our efforts to understand the bioimmunological role
for CRP have focused on carefully examining its higher
order structure (i.e., secondary, tertiary, and quater-
nary) and the changes to subunit structure when dis-
sociated from the CRP pentameric disk. We discovered
that when pCRP subunits are separated, they undergo a
notable conformational change which markedly affects
CRP solubility, antigenicity, biodistribution, cellular, and
humoral reactivities (Potempa et al. 1983, 1987; Ying
et al. 1989; Schwedler et al. 2006; Wu et al. 2007; Wang
et al. 2011). Furthermore, we found that these struc-
tural changes can occur undetected and to various
extents in CRP test reagents and CRP experimental
systems (Potempa et al. 1987; Khreiss et al. 2004a, b; Ji
et al. 2007). Of signiﬁcance, if mCRP generation was not
recognized and controlled for, it may have been present
in CRP reagents used by various investigators,
inﬂuencing experimental observations and confounding
conclusions reached regarding CRP’s exact biological
role.
To more carefully study the free subunit isoform of
CRP, designated as monomeric, modiﬁed CRP (i.e.,
mCRP), a recombinant protein reagent was engineered
and expressed in Escherichia coli. While signiﬁcant
amounts of protein were produced after induction, the
inherent insolubility of the manufactured recombinant
analog of mCRP, (termed rmCRP), was manifest as dif-
ﬁcult-to-process inclusion bodies. Herein we describe a
method to solubilize and purify rmCRP and present
evidence for its usefulness as a comparable and effective
reagent for examining the differential characteristics of
mCRP.
We describe a simple, reversible method to solubilize
inclusion body aggregated rmCRP using citraconic
anhydride. The solubilized protein was efﬁciently and
effectively processed by hydrophobic and anion
exchange chromatographic methods to produce highly
puriﬁed, endotoxin-free protein. This puriﬁed protein is
structurally, antigenically, and functionally analogous to
biologically generated mCRP and represents a useful
and advantageous reagent for the expanded study of the
conformationally distinctive CRP-free subunit (Zouki
et al. 2001; Khreiss et al. 2002; Ji et al. 2006a, b).
RESULTS
Preparation of biological modiﬁed (mCRP)
from native (pentameric) CRP (pCRP)
Biological pentameric CRP (pCRP) was puriﬁed from
human pleural or ascites ﬂuids using calcium-depen-
dent afﬁnity chromatography to phosphorylcholine-
substituted agarose resin essentially as described
(Potempa et al. 1987). Afﬁnity bound protein was eluted
with citrate and was subsequently processed on
Q-Sepharose anion exchange to reduce endotoxin con-
tamination and improve purity. Eluted protein was
immediately dialyzed into 25 mmol/L Tris–HCl,
0.15 mol/L NaCl (pH 7.4) containing 2 mmol/L CaCl2,
sterile ﬁltered and stored at 4 C. It is important to note
that storage of native CRP at 4 C without calcium, or in
the presence of cheating reagents, will result in a slow,
spontaneous conversion of pCRP into the mCRP con-
former. Storage of pCRP at temperatures below freezing
is not recommended as irreversible alterations in pen-
tameric CRP protein conformation have been observed.
mCRP was prepared from puriﬁed pCRP pentamer
using urea chelation (i.e. biological mCRP) (Potempa
rmCRP protein puriﬁcation using anhydride reagents METHODS
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et al. 1983, 1987). Speciﬁcally, ultrapure urea was dis-
solved to 8 mol/L into a pCRP solution, and EDTA was
added to 10 mmol/L. The solution was incubated for
1 h at 37 C and then exhaustively dialyzed into
25 mmol/L Tris–HCl, (pH 8.3). Under these conditions,
the maximum solubility of mCRP was found to be
0.6 mg/mL. The addition of [0.1 mol/L sodium or
potassium chloride, or 1 mmol/L CaCl2, MnCl2, NiCl2, or
ZnCl2, 3.5 mmol/L MgCl2, or 0.1 mmol/L FeCl2 resulted
in the immediate self-aggregation of mCRP into an
opalescent suspension (i.e., reduced aqueous solubility).
By electron microscopic analysis, pCRP is seen as a
tightly compacted pentameric disk of ﬁve globular
subunits surrounding an annular void in agreement
with the protein structure deﬁned by crystallization
analyses (Shrive et al. 1996) (Fig. 1A). Biological mCRP
is seen to exist as short but fat ﬁber aggregates that do
not appear to be dense structures but rather loose
associated short rod-like structures (Fig. 1B). mCRP
molecules in the absence of added salt or in the pres-
ence of membranes were seen to associate into diffuse
matrix-like structures very distinct from the annular
pentameric pCRP disk. In the presence of salt, the mCRP
diffuse aggregates are seen to condense into large
homogeneous electron dense clusters (Ji et al. 2007;
Motie et al. 1996).
Puriﬁcation of cys-mutated rmCRP
from inclusion bodies
The E. coli expressed rmCRP protein deposited as highly
aggregated, insoluble inclusion bodies. Numerous solu-
bilization methods including up to 8 mol/L urea, up to
6 mol/L guanidinium hydrochloride, low and high ionic
strength salt solutions, addition of arginine or protic
solvents such as n-propyl alcohol, addition of ionic (e.g.,
SDS) and non-ionic (e.g., Triton X 100) detergents at
various concentrations, and increasing pH values[ 12.0
were tried with limited or no success. Each method,
including different combinations of each, was insufﬁ-
cient to allow for chromatographic puriﬁcation, was
found to interfere with biochemical separation
methodologies, or was found to be too harsh and
damaging to protein integrity.
The dilemma of how to solubilize the cys-mutated
rmCRP was solved by a serendipitous observation on the
solubility of biological mCRP while investigating the
amino acid residues in the CRP sequence/structure that
contributed to mCRP binding activity for immune
complexes (Motie et al. 1996). Various site-speciﬁc
modiﬁcation reactions were performed on biological
mCRP to block or alter selected amino acid R groups
prior to performing binding assays. A brief summary of
Fig. 1 Visualization of pCRP, biological mCRP, and C-rmCRP. Visualizing the distinct structural differences between the pCRP pentameric
disk conformer and the subunit mCRP ﬁbrous-like conformer, whether produced from the pCRP protein (bio-mCRP) or by recombinant
expression (C-rmCRP). A 2 lL droplet of sample was added to a freshly glow-discharged carbon-coated 300 mesh copper EM grid for 10 s
followed by staining with 1 % PTA for 60 s. Grids were observed in a Tecnai G20 (FEI) 200 kV EM. All magniﬁcations are 50,0009.
Pentametic CRP (pCRP) A is seen to exist as cyclic pentameric discoids of tightly packed subunits surrounding a central void with an
average diameter of 10.42 ± 0.08 nm (n = 200). Biological mCRP (Biol-mCRP) B was produced from pCRP using urea chelation (see
Method). It is seen to exist as short, fat ﬁbrous aggregates with an average diameter of 14.45 ± 0.33 nm (n = 20). Citraconylated,
recombinant modiﬁed CRP (C-rmCRP) c exists primarily as short, thinner ﬁbers. An average diameter of 9.92 ± 0.24 nm (n = 25). The
scale bars represent 50 nm
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reagents used and the general effects on immune com-
plex binding is shown in Table 1.
These studies established that anionic groups and
tryptophan residues on the mCRP structure are
required for binding aggregated (complexed) IgG
structures. More relevant to this report, it was noted
that modiﬁcation of primary amine residues with vari-
ous anhydride reagents notably increased mCRP solu-
bility. A systematic evaluation of various anhydride
reagents (i.e., succinyl, maleic, and citraconic anhy-
drides) all effectively increased the solubility of mCRP.
Furthermore, even though anhydride modiﬁcation
resulted in changing the positive charge on primary
amine residues to negatively charged carboxyl groups,
such changes were not detrimental to the studied mCRP
binding activities, nor its antigenicity using monoclonal
antibodies speciﬁc for the mCRP isoform (Ying et al.
1989, 1992). Because of the desire to allow for facili-
tated removal of the acyl groups for directed studies,
and because citraconic anhydride is supplied as a liquid
reagent that can be easily aliquoted, it was chosen as the
preferred solubilizing agent for processing inclusion
body aggregated cys-mutated rmCRP.
Solubilization of inclusion body protein using
citraconic anhydride
To approximately 20 mL inclusion body at 60 mg/mL
protein, approximately 150 mL 0.1 mol/L NaHCO3 (pH
9) was added and stirred to form a homogeneous sus-
pension. While stirring, a 200 lL aliquot of citraconyl
anhydride was added to the suspension, and the pH was
continuously monitored. At these slightly basic condi-
tions, primary amines are nucleophilic and will readily
react with the added anhydride reagent. As the reaction
proceeded, the pH of the solution dropped, slowing the
reaction rate. To maintain high efﬁciency of acylation,
the suspension pH was continually monitored so to
maintain a reaction pH at 9.0 by adding drops of 1 N
NaOH. As anhydride reagent was depleted, the pH
change slowed or stopped. Additional aliquots of citra-
conic acid (up to 10 for the system described here) were
added and the cycle repeated. While all IB protein was
modiﬁed to some extent, not all precipitated materials
in the inclusion body suspension immediately solubi-
lized at this step.
After the pH stabilized with the ﬁnal addition of
anhydride reagent, the inclusion body slurry was cen-
trifuged at 30009g at 4 C for 30 min. Care was taken
not to pellet the protein at such high centrifugal forces
that would cause the protein to compact, complicating
recovery of the precipitate for base-induced solubiliza-
tion (see below). The soluble supernate (containing
citraconylated cys-mutated rmCRP (i.e., C-rmCRP) and
various other inclusion body contaminants) was col-
lected and was immediately passed on a Phenyl
Sepharose hydrophobic adsorption column. The non-
solubilized citraconic anhydride-treated inclusion body
pellet that was collected by centrifugation, resuspended
in 0.1 mol/L NaHCO3 (pH 8.5) and solubilized by a brief
exposure to pH [ 12.0 (using 5 N NaOH). After the
base-solubilized protein clariﬁed, the pH was quickly
returned to pH 8.5 by the addition of 6 N HCl. This base-
solubilized sample remained soluble indicating it too
has been sufﬁciently modiﬁed by acylation to enhance
inclusion body solubilization. Approximate half of the
cys-mutated rmCRP in the starting inclusion body sam-
ple was found to directly solubilize using the method
described here, and half required a brief exposure to
high pHs to achieve solubilization.
Phenyl Sepharose hydrophobic adsorption
chromatography
Phenyl Sepharose (high substitution, fast ﬂow)
hydrophobic adsorption resin (350 mL in a
3.0 9 50 cm column) was equilibrated in 0.1 N NaHCO3
(pH 8.5). Solubilized C-rmCRP, containing approximately
Table 1 Group-speciﬁc modiﬁcation reagents used to affect mCRP- aggregated IgG interactions
Amino acid group targeted Group modiﬁcation
reagent
Reaction of aggregated IgG
with group-modiﬁed mCRP
Reaction of mCRP with group-
modiﬁed aggregated IgG
Epsilon amino group of lysine NHS biotin Strong binding No binding
Guanidino group of arginine p-hydroxyphenylglyoxal Strong binding Strong binding
Indole ring of tryptophan BNPS-Skatole Decreased binding Strong binding
Phenyl ring of Tyrosine Tetranitromethane Strong binding Decreased binding
Carboxyl groups of aspartic
and glutamic acid
Diazo nor-leucine methylester Decreased binding Strong binding
Sulfhydryl group of cysteine N-ethyl maleimide Strong binding Strong binding
Thiomethyl group of Methionine Hydrogen peroxide Strong binding Strong binding
As summarized from studies reported by Motie et al. (1996)
rmCRP protein puriﬁcation using anhydride reagents METHODS
 The Author(s) 2015. This article is published with open access at Springerlink.com 21 | August 2015 | Volume 1 | Issue 1
600 mg protein, was directly applied at a ﬂow rate of
4 mL/min. Non-bound material was collected and found
to be essentially protein free, containing cell breakage
debris that had signiﬁcant absorbance at 260 nm and
minimal absorbance at 280 nm.
After extensive washing with 0.1 mol/L NaHCO3, the
resin-adsorbed protein was further washed and equili-
brated with 0.1 mol/L Na/K Phosphate buffer (pH 7.4).
The ratio of sodium to potassium ions in this buffer was
achieved by mixing dibasic sodium phosphate and
monobasic potassium phosphate until the desired pH of
7.4 was reached.
Loosely adsorbed contaminants were removed by
passing 1 mol/L NaCl in 0.1 mol/L Na/KPO4 (pH 7.4).
Additional contaminants and C-rmCRP fragments and
aggregates were eluted using 3 mol/L Guanidinium HCl
(GuHCl) in0.1 mol/LNa/KPO4 (pH7.4). Thiswas followed
by passage of 6 mol/L GuHCl in 0.1 mol/L Na/KPO4 (pH
7.4), where C-rmCRP effectively eluted (Fig. 2A).
The 6 mol/L GuHCl eluted pool was simply diluted 1
 5 with RO water. This method reduced the effective
GuHCl concentration to *1 mol/L and resulted in
immediate precipitation of all C-rmCRP in the eluted
pool which was clearly visible. The diluted precipitated
eluate was allowed to equilibrate at 4 C overnight with
gentle stirring. The precipitate was then collected as
described above by centrifugation at 30009g at 4 C for
30 min. The diluted GuHCl supernatant was decanted
and discarded. The centrifuged precipitate was gently
resuspended in 0.1 mol/L NaHCO3 (pH 8.5) and then
resolubilized by slow addition of 5 N NaOH until the pH
was raised above 12.0. Once the protein solution clari-
ﬁed, the pH was quickly brought back down to pH 8.5
with the addition of 6 N HCl under which conditions the
protein remained soluble. Of note, exposure of the
protein to these high pH values was limited to as short a
time as possible to avoid base-induced protein
modiﬁcation.
Fig. 2 Chromatographic elution proﬁles of C-rmCRP from inclusion bodies. Demonstration of representative elution proﬁles of
citraconylated recombinant mCRP from inclusion body preparations. A Phenyl Sepharose (high substitution, fast ﬂow) hydrophobic
adsorption resin (3.0 9 50 cm) was equilibrated in 0.1 N NaHCO3 (pH 8.5) and Citraconylated Inclusion bodies of E. coli expressed
rmCRP, containing approximately 600 mg protein, was applied at a ﬂow rate of 4 mL/min. After washing and equilibration in neutral
phosphate buffer, protein fragments and aggregates eluted with passage of 3 mol/L GuHCl (see representative SDS-PAGE analysis in a
inset). C-rmCRP (SDS-PAGE app Mw of 23 kD) eluted with passage of 6 mol/L GuHCl. B After collection and processing (See Methods), the
eluted C-rmCRP was further processed on DE Sepharose fast ﬂow anion exchange resin (3.0 9 50 cm column), remaining bound using
2 mol/L GuHCl and eluting using 5 mol/L GuHCl. Puriﬁed C-rmCRP calculated Mw = 23,488 (B inset)
METHODS L. A. Potempa et al.
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DE Sepharose anion exchange chromatography
DE Sepharose fast ﬂow anion exchange resin (350 mL in
a 3.0 50 cm column) was equilibrated in 0.1 N NaHCO3
(pH 8.5). Of note, use of the stronger anion exchange
Q-Sepharose resin is not recommended for the puriﬁ-
cation of C-rmCRP as increased levels of fragmentation
were noted in ﬁnal eluted protein.
The resolubilized Phenyl Sepharose 6 mol/L GuHCl
eluate was directly applied and bound to the DE
Sepharose resin. The column was exhaustively washed
with 0.1 mol/L NaHCO3 (pH 8.5), which was then
equilibrated in 0.1 mol/L Na/KPO4 buffer (pH 7.4).
Loosely bound contaminants were removed by washing
with 1 mol/L NaCl in 0.1 mol/L Na/K PO4 (pH 7.4).
Protein fragments and other contaminants were
eluted with 2 mol/L GuHCl in 0.1 mol/L Na/K Phos-
phate buffer (pH 7.4) followed by elution of the main
protein peak with 5 mol/L GuHCl in Na/KPO4 buffer
(Fig. 2B).
The eluted protein was processed exactly as described
above with 6 mol/L GuHCl Phenyl Sepharose eluate. The
pooledpeakwasdiluted 15with ROwater to reduce the
GuHCl concentration, which led to protein self-aggrega-
tion. Aggregates were collected by centrifugation, resus-
pended in 0.1 mol/L NaHCO3, and solubilized by adding
5 N NaOH until the solution clariﬁed. The resolubilized
protein was quickly neutralized and was exhaustively
dialyzed into a ﬁnal buffer of choice—most generally into
25 mmol/L Na phosphate buffer containing 0.15 mol/L
NaCl (pH 7.4) (i.e., 25 mmol/L NaPBS).
The ﬁnal processed protein pool was sterile ﬁltered
through 0.2 lm membranes. Protein concentration was
measured by BCA assay and by absorbance at 280 nm,
using Beer’s law. SDS-PAGE analysis (see inset, Fig. 2B),
indicated that the C-rmCRP was[95 % pure with an
apparent molecular weight of 23,488 daltons.
Unpuriﬁed, non-citraconylated starting inclusion
body protein (i.e., crude inclusion body protein) was
solubilized using SDS detergent and run on SDS-PAGE
gels for direct comparison to the puriﬁed C-rmCRP
protein. Crude inclusion body protein was predomi-
nantly rmCRP (minimal contaminating bands were also
observed) and migrated with an apparent molecular
weight of 22,827 (data not shown). The difference in
size between the Citraconylated rmCRP and the non-
citraconated rmCRP (i.e., 661 daltons) is consistent with
substitution of 6 citraconyl groups on the derivatized
protein (based on a molar weight of 112 daltons for
each citraconyl group). These data are consistent with
calculations of molar substitution based on the anhy-
dride reagent extinction coefﬁcient and absorbance
measurements at 250 nm (see Methods).
The recovered C-rmCRP retained a high level of sol-
ubility even in saline-based buffers (up to *6.5 mg/
mL). The fact that the highly concentrated protein could
pass through 0.2 lm Acrodiscs suggest that the protein
is not forming microaggregates that would otherwise
clog ﬁlter membranes.
Procedure for removing citraconyl groups (if
desired)
Citraconyl groups are removed from the C-rmCRP by
simple dialysis into 0.05 mol/L Citrate, pH 3.5, for 2 h at
RT. The puriﬁed rmCRP protein will self-aggregate and
form a suspension which remains when the decitra-
conylated protein is re-equilibrated into saline-based
buffers of neutral pH. The opalescent suspension is
visually similar to that observed for biological mCRP
when urea-chelated mCRP is dialyzed into saline-based
buffers to remove urea.
SDS-PAGE and western blot analysis
Western blot analysis using monoclonal antibodies
speciﬁc for the mCRP isoform (Ying et al. 1989, 1992),
verifying that the main isolated protein band was
[95 % pure and consistent with a free CRP subunit size
(i.e., 23 kDa). It exhibited antigenicity similar to the
mCRP and not pCRP antigen (data not shown).
Amino acid composition
Puriﬁed non-citraconylated rmCRP was analyzed for
amino acid composition by standard analysis and was
found to contain the same number of amino acid resi-
dues per mole of protein as the biologically puriﬁed CRP
subunit. Eleven alanine residues were quantiﬁed per
mole of recombinant CRP compared to 9 per mole of
mCRP, and two cysteine residues were quantiﬁed per
mole of mCRP while none were detected in rmCRP.
Three methionine resides were quantiﬁed per mole of
rmCRP compared to two in the biological CRP subunit.
These results corroborate the changes engineered in the
recombinant CRP subunit and verifying the expressed
protein is in other ways identical to the biologically
derived CRP molecule. These procedures were per-
formed under contract by Analytical Biotechnology
Services, Boston, MA.
N-terminal sequence analysis of rmCRP
Non-citraconylated rmCRP was bound to a Biobrene-
treated glass ﬁlter, and the N-terminal residues were
cleaved using phenyl isothiocyanate (PITC) in a pulsed
rmCRP protein puriﬁcation using anhydride reagents METHODS
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liquid sequencer with an in-line Phenyl-thiohydantoin
amino acid analyzer. The cycle was repeated 15 times to
determine the N-terminal sequence of the rmCRP pro-
tein. The sequence determined—MQTDMSRKAFVFP
KE—exactly corresponds to the sequence established
for the CRP subunit (Shrive et al. 1996). This analysis
was performed under contract by Analytical Biotech-
nology Services, Boston, MA.
Peptide mapping and mass spectroscopy
of rmCRP
Non-citraconylated rmCRP and mCRP were solubilized
in 8 mol/L urea and were treated with dithiothreitol
and iodoacetate. The samples were diluted four-fold and
were digested with endoproteinase Lyc-C. Digests were
separated on reverse phase C-18 HPLC resin using an
acetonitrile gradient in the presence of TFA. Separated
peptides were analyzed for mass using electrospray
mass spectroscopy.
Lys-C digested rmCRP produced peptide maps that
matched closely to those maps generated with the bio-
logical CRP subunit. No major amino acid substitutions
were present in the recombinant product that would
results in segments of the protein that are different from
segments of the biological CRP subunit. These analyses
were performed under contract by the Protein and
Carbohydrate Structure Facility, Ann Arbor, MI.
Serum protein electrophoresis of pCRP, mCRP
and citraconylated rmCRP
CRP pentamer (pCRP) migrates as a gamma globulin by
Serum Protein electrophoresis, having an apparent iso-
electric point of 6.3 ± 0.2 (Laurent et al. 1983; Potempa
et al. 1983). Based on its primary amino acid sequence,
the calculated isoelectric point for CRP is 5.3, which
would be expected to have alpha rather than gamma
electrophoretic mobility (Potempa et al. 1983). When
pCRP is converted into the mCRP, the mCRP is seen to
now migrate toward the anode in the predicted alpha
zone (Fig. 3). Due to the added negative charges after
rmCRP is acylated with citaconic anhydride, the anion-
ized protein is seem to migrate with pre-albumin anodal
electrophoretic mobility.
Antigenicity comparisons of native CRP, mCRP,
and all forms of rmCRP
Various monoclonal antibodies have been developed,
which speciﬁcally react with the pCRP and mCRP iso-
forms (Ying et al. 1989). Of note, direct adsorption of
pCRP onto plastic surfaces will result in the loss of pCRP
antigenicity and the expression of mCRP antigenicity.
Hence, to monitor pCRP antigenicity in solid phase
assays, pCRP must be captured onto a speciﬁc ligand
that is directly adsorbed to the plastic surface (e.g.,
Fig. 3 Serum protein Electrophoresis of pCRP, mCRP, and C-rmCRP. Comparing the electrophoretic mobility of mCRP produced from the
pCRP after urea chelation to pCRP mobility. The conversion of pCRP to mCRP increased the electrophoretic mobility of CRP from gamma
to alpha. The effect of solubilizing recombinant mCRP with citraconic anhydride (C-rmCRP), which changes primary amine residues to
carboxyl residues is shown for comparison. The anionized rmCRP displays rapid pre-albumin mobility
METHODS L. A. Potempa et al.
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Fig. 4 Antigenic comparison of pCRP, mCRP, and C-rmCRP. Demonstration of dual CRP speciﬁcities in a polyclonal anti-CRP reagent.
Evaluation of a polyclonal anti-CRP reagent for binding speciﬁcity to pCRP and mCRP antigens. ELISA analyses were performed using
various primary coat concentrations and various dilutions of deﬁned monoclonal anti-CRP reagents (Ying et al. 1989, 1992) and a
representative polyclonal anti-CRP reagent. In this analysis, results are shown for an IgG fraction anti-Human C-reactive protein
antiserum produced in rabbits (see Methods). A depicts the ELISA construct to detect pCRP. Phosphorylcholine-substituted KLH (PC-KLH)
was ﬁrst immobilized on ELISA polystyrene surfaces before pCRP was captured as a function of calcium. B depicts the ELISA construct to
detect mCRP. mCRP was produced from pCRP by urea chelation and was directly immobilized onto the plate surface. Of note, direct
immobilization of the CRP pentamer onto the polystyrene surface will result in loss of pCRP structure and expression of mCRP structure
(see below, E). C demonstrates the antigenic reactivity of anti-pCRP monoclonal antibody 1D6 for PC-captured pCRP and directly
comparable reactivity of the rabbit anti-CRP polyclonal reagent. The anti-mCRP monoclonal antibody 3H12 shows no reactivity for PC-
captured pCRP antigen. D demonstrates the antigenic reactivity of these same antibody reagents at the same tested concentrations for the
mCRP antigen. These results show that while monoclonal anti-mCRP 3H12 now shows signiﬁcant and distinctive reactivity, anti-pCRP
monoclonal antibody1D6 is non-reactive. The rabbit anti-CRP polyclonal reagent, however, shows substantial reactivity for the mCRP
antigen. E demonstrates the effect of directly immobilizing native CRP on the plate surface, demonstrating that the pCRP antigenicity is
lost and the mCRP antigenicity is expressed when CRP is adsorbed onto the plastic surface. F shows a least-squares analysis comparing
the relative reactivity of the rabbit anti-CRP polyclonal reagent used herein. Equivalent concentrations of either pCRP and mCRP antigens
were immobilized, and various dilutions of polyclonal reagents were reacted under equivalent experimental conditions. Quantiﬁed
reactivity was plotted as a function of antiserum dilution, and the level of reactivity for each antigen was normalized using the regression
analyses. Results show the rabbit anti-CRP reagent tested expressed both pCRP and mCRP antigenic speciﬁcity and that the mCRP
reactivity represented between 25 and 33 % the pCRP antigenicity measured. This analysis was repeated multiple times using multiple
levels of immobilized antigens using various other commercially available anti-CRP reagents made in different species, and in anti-CRP
polyclonal antiserum made in our laboratory. The results shown here are representative of all polyclonal anti-CRP reagents tested
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using CRP calcium-dependent speciﬁcity for phospho-
rylcholine (substituted on keyhole limpet hemocyanin
(PC-KLH)), or to antibodies that are speciﬁc for native
CRP) (the construct is shown in Fig. 4A).
PCRP and mCRP antigens are clearly differentiated
using these monoclonal antibodies. Anti pCRP mAb 1D6
strongly reacted with captured pCRP and not with
mCRP (Fig. 4C) while the mAb 3H12 strongly reacted
with mCRP and not with captured pCRP (Fig. 4D). Using
identical assays as just described, a representative
polyclonal rabbit anti-human CRP reagent was screened
for speciﬁcity to both pCRP and mCRP antigens. The
reagent was found to have strong reactivity to both
isoforms (Fig. 4C, D). Similar assays have been per-
formed using other polyclonal anti-CRP reagents (e.g.,
produced in goat, sheep, etc.) with similar results,
indicating reagents labeled as ‘‘anti-CRP’’ have a high
probability of containing dual speciﬁcity to both the
pCRP and the mCRP antigen (Samberg et al. 1988).
Furthermore, the widely used anti-CRP monoclonal
reagent known as Clone 8 (Sigma-Aldrich), was also
screened using these assays and found to be predomi-
nantly speciﬁc for the mCRP and not the pCRP antigen
(Schwedler et al. 2003).
Both crude and puriﬁed C-rmCRP produced in E. coli
express mCRP and not pCRP epitopes. mAbs directed to
the C-terminal octapeptide of the CRP subunit, which is
only expressed in the mCRP isoform (Ying et al. 1992)
react with the same speciﬁcity and afﬁnity to mCRP, rm-
CRP, and to alkylated or de-alkylated forms of rmCRP. A
mAb that reacts with a sequence of mCRP that involves
residue cysteine 36 (i.e., mAb 8C10) shows lesser reac-
tivity with all rmCRP proteins, suggesting that the C36A,
C97A mutations that remove the CRP subunit disulﬁde
bond, do inﬂuence expression of the epitope recognized
by this mAb. All other mAbs tested showed comparable
reactivity of mCRP and rmCRP. Hence, based on sequence,
solubility, and antigenicity characteristics, recombinant
mCRP is directly comparable to biological mCRP.
When the polyclonal reagent is titered on various
levels of immobilized antigens and its relative reactivity
for pCRP and mCRP is compared, a linear regression
analysis allows for an estimation of the percent of mCRP
speciﬁcity in the anti-CRP polyclonal reagent. Using this
analysis (Fig. 4F) the representative rabbit anti-CRP
polyclonal reagent shown herein was estimated to have
from 25 to 33 % speciﬁcity for the mCRP antigen.
Higher order structure of CRP, mCRP,
and C-rmCRP
CRP is a highly soluble protein comprised ﬁve globular
subunits arranged in cyclic symmetry. Its three-
dimensional structure, determined and reﬁned using
X-ray crystallographic analyses (Shrive et al. 1996) and
Fourier transform infrared spectroscopy analysis (Dong
et al. 1994), assigns pCRP a secondary structure of
50 % b-sheet, 12 % helix, 24 % b turn, and 14 %
unordered structure.
When pCRP is dissolved in increasing amounts of
urea, it is found to undergo a two-stage structural
change as analyzed by Circular dichroism (CD). When
urea is increased up to 4 mol/L, pCRP undergoes
tertiary structural changes that are consistent with
formation of a molten globular structure; secondary
structures remain unchanged indicating hydrogen
binding forces contributing to helical and beta sheet
structures that remain intact. When urea is increased
above 4 mol/L, pCRP pentamer dissociates with a
substantial loss in secondary structure, shown by a
sharp increase in ellipticity at 216 nm (data not
shown).
When urea is removed by dialysis and the mCRP
isoform is expressed, some, albeit not as well-organized
secondary structure returns, which appears to be pre-
dominantly beta structure. C-rmCRP CD spectra was
similar to that observed for mCRP and was distinct from
pCRP (data not shown).
DISCUSSION
Perhaps the most fundamental biochemistry axiom
describing proteins is that structure regulates function.
While an understanding of protein structure begins by
examining its primary sequence, its secondary, tertiary,
and quaternary structures and their dynamic inter-
change are key elements in deciphering and under-
standing true biological function. Many proteins exist as
precursor molecules, storing critical activation energies
in precursor conformations, releasing potential energies
when protein structure changes to expose sites needed
to drive biochemical or immunological reactions (Del-
lisanti et al. 2011; Tompa 2012; Cook and Hogg 2013).
Multiple structural forms of CRP have been recog-
nized for years. Hokama et al. (1967) reported that
serum CRP was present in 2 forms—a gamma migrating
form and a low mobility form. These forms intercon-
verted when mixed with normal serum. Wang et al.
(2002) reported that CRP exists in 3 forms—(1) a
pentameric ring; (2) a small globulin-like (monomeric)
form; and (3) a ﬁbril-like structure. The globulin-like
monomers were found on negatively charged mem-
branes in the absence of calcium and were structurally
stable. The identity of and interrelationship between
these and other structural forms of CRP in various
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solvents and membrane experimental systems, and
their biochemical and immunological characteristics,
continue to evolve (Potempa et al. 1983, 1987; Ying
et al. 1989, 1992; Zouki et al. 2001; Khreiss et al. 2002,
2004b; Ji et al. 2006a, b; Schwedler et al. 2006; Ji et al.
2007; Wu et al. 2007; Wang et al. 2011). Most funda-
mentally, CRP appears to exist in two primary structural
forms: (1) a serum soluble cyclic pentameric discoid
molecule (i.e., pCRP) and (2) a conformationally, anti-
genically, and functionally distinctive free subunit (i.e.,
mCRP) which is predominantly tissue-based and poorly
soluble.
The widely known and studied cyclic pentamer has
been crystalized and its three-dimensional structure
published in static form (PDB: 1GNH; 1B09) (Shrive
et al. 1996; Thompson et al. 1999; Mikolajek et al.
2011). The concentration of this hepatically synthesized,
serum-based protein is a key diagnostic index for the
presence of inﬂammation somewhere in an individual
(Kushner 1982; Macintyre et al. 1982; Morley and
Kushner 1982; Macintyre et al. 1985; Gewurz et al.
1995; Gabay and Hushner 1999; Vigushin et al. 1993;
Black et al. 2004; Marnell et al. 2005; Ma et al. 2013;
DuClos 2013; Agrawal et al. 2014). Numerous reports
have appeared since 1986, however, showing that CRP
is also produced extrahepatically (primarily proven
using mRNA hybridization techniques and immunohis-
tochemical analyses), and that antigens related to CRP
are widely found not only in serum, but also in various
healthy and diseased tissues, including the kidney (Kuta
and Baum 1986; Dong and Wright 1996; Yasojima et al.
2001; Calabro´ et al. 2003; Jabs et al. 2003; Ciubotaru
et al. 2005; Sattler et al. 2005; Haider et al. 2006;
Krupinski et al. 2006; Wilson et al. 2007; Eisenhardt
et al. 2009; Slevin et al. 2010). This tissue-based isoform
of CRP is sometimes expressed intracellularly, or tightly
bound to membranes, being more characteristic of what
is currently known of the mCRP protein. Because both
pCRP and mCRP proteins are derived from the same
mRNA and because of questions concerning the exact
speciﬁcity of antibody reagents used to immunochemi-
cally identify CRP antigens (Fig. 4; Samberg et al. 1988;
Schwedler et al. 2003), many published reports should
be interpreted with caution as to which conformational
form of CRP was actually being synthesized in various
tissue sites.
Experimental evidence for CRP structural changes
has been measured by a loss in intrinsic tryptophan
ﬂuorescence and in an increase in exposure of
hydrophobic binding sites reactive with the ﬂuorescent
dye ANS (Potempa et al. 1983, 1987; Ji et al. 2006a, b,
2007). Additionally, the increased electrophoretic
migration of mCRP compared to pCRP (Fig. 3) is an
experimental proof that salt-bridge electrostatic charges
reported to stabilize the tightly compacted and associ-
ated pCRP (Thompson et al. 1999; Agrawal and Chak-
raborty 2013) are broken when mCRP is expressed.
When these intramolecular forces are relaxed, the free
electrostatic charges now allow the protein to migrate
faster (as an alpha globulin) contrasted to the reported
gamma migration for pCRP (Laurent et al. 1983). Of
note, literature reports have appeared noting aberrantly
migrating CRP in certain disease conditions (Hokama
et al. 1967; Hood 1977; Abdulla and Hamadah 1981),
suggesting a potential pathological relevance for differ-
ent isoforms of CRP.
pCRP is known to be stabilized by hydrophobic forces
that manifest both at subunit interfaces and in the
central core of each of the globular subunits. When
mCRP is formed from pCRP, the increased aqueous
exposure of these hydrophobic regions promotes mCRP
self-aggregation, lowering solubility, and leading to ﬁbril
formation (Fig. 1; Wang et al. 2002). The hydrophobic
and electrostatic salt-bridges that contribute to the
compact tertiary and quaternary structures of pCRP also
explain its resistance to proteolysis (Kinoshita et al.
1989); the more relaxed, albeit aggregated mCRP, is
found to be much more sensitive to various proteases.
Indeed, cleavage of mCRP yields formation of biologi-
cally active peptides, such as the C-terminal hexapeptide
which has potent anti-inﬂammatory actions (El Kebir
et al. 2011).
As more is learned about the distinctive structures
and functions of each CRP isoform, the question arises
as to how and where mCRP might be generated and
whether mCRP might contaminate pCRP test reagents.
Indeed, pCRP has been seen to spontaneous convert
into mCRP if stored without calcium or in the presence
of chelating agents (Potempa et al. 1987; Wang et al.
2002; Khreiss et al. 2004a). Furthermore, even in the
presence of calcium, pCRP converts in a step-wide
fashion, into mCRP when incubated for more than 4 h
with cells in tissue culture maintained at 37 C, or with
liposomes (Khreiss et al. 2004a; Ji et al. 2006b, 2007).
Hence, any extended incubation of pCRP with mem-
branous experimental systems past 4 h may reﬂect to
some extent on the distinctive bioactivities of mCRP. The
long history of contradictory reports on CRP may be
related to this possibility.
The need for mCRP reagents that can be used for
comparative and individualized studies is of paramount
importance. Herein, we report on a genetically engi-
neered recombinant form of mCRP (rmCRP) and its
usefulness as a structural and functional analog of bio-
logically generated mCRP. Selected site-directed muta-
genesis was performed to substitute alanine residues
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for both cysteine residues in the CRP subunit primary
sequence, producing a protein that lacks the capacity to
form disulﬁde-linkages. The importance of disulﬁde
reduction as a key regulation mechanism for mCRP
binding to lipid raft microdomains has been clearly
demonstrated (Wang et al. 2011).
rmCRP was expressed in E. coli as a highly insoluble
aggregated inclusion body, which complicated puriﬁca-
tion and characterization analyses. We report that acy-
lation of primary amine residues using various
anhydride reagents effectively dissociated the
aggregates and made the rmCRP protein extremely sol-
uble in aqueous solvents. Furthermore, acylation with
reagents that reversed the charge of the primary amines
did not affect rmCRPs hydrophobic binding character-
istics, allowing for large scale, efﬁcient use of
hydrophobic adsorption chromatography as a ﬁrst step
in puriﬁcation. The strong, high-yield absorption to this
hydrophobic surface allowed various and aggressive
washing steps which removed cellular debris and pro-
tein fragments, and endotoxin that was present in E. coli
cellular debris during collection of inclusion bodies.
Fig. 5 Flow chart for the processing and puriﬁcation of C-rmCRP
METHODS L. A. Potempa et al.
28 | August 2015 | Volume 1 | Issue 1  The Author(s) 2015. This article is published with open access at Springerlink.com
C-rmCRP elution from the hydrophobic adsorption col-
umn required 6 mol/L Guanidinium HCl. Simple dilu-
tion of the guanidinium eluate leads to rmCRP
precipitation, which allowed for quick recovery, con-
centration, resolubilization in base, sterile ﬁltration, and
facile exchange into chosen buffers for experimental
needs. The puriﬁcation scheme used to purify rmCRP is
summarized in Fig. 5.
The use of anhydride reagents to alter solubility and
activity of various proteins has been reported. Liu and
Wang (Liu and Wang 2007) showed modiﬁcation of
chloroperoxidase with maleic anhydride, citraconic
anhydride, or phthalic anhydride could improve activity
and stability. Shet and Madaiah (1988) showed such
chemical modiﬁcations could affect immune complex
binding, antigenicity, and hemagglutination activity of
lectins. Khan and Suriola (1982) showed citraconyla-
tion could control the hemagglutination and sugar
binding activity of Caster Bean Agglutination. Son et al.
(2009) used citraconic anhydride to control the prote-
olytic activity of trypsin-like enzymes in the recombi-
nant expression, recovery, and yields of proinsulin in E.
coil.
The biochemical, immunological, and functional
activities of C-rmCRP were shown to be comparable to
biological mCRP, making the recombinant protein an
excellent and advantageous research reagent for the
study of mCRP. Furthermore, by using citraconylation
(in preference to maleylation and succinylation), the
acyl groups can be readily removed by short dialysis
into citric acid (pH 3.5). Removal of the acyl group does
cause rmCRP to lose solubility forming ﬁbril-like struc-
tures that look more like mCRP than pCRP (Fig. 1C). It is
interesting to speculate whether such ﬁbrous-like
structures are related to the tissue-deposited mCRP
antigen recognized in many studies.
CRP has many homologues in the blood and hemo-
lymph of vertebrates and invertebrates, including the
horseshoe crab, which has survived millions of years of
evolution (Shrive et al. 1996). In elucidating the true
function of CRP in humans and in lower species, one
must look beyond its possible role in disease pathology
and inﬂammation, and consider its conceivable role as a
key protein of innate immunity, and a necessity factor
for general health and survival. As more is learned and
appreciated about multiple CRP structures, a reexami-
nation of the role of each isoform of CRP is called for, not
only as the prototypic acute phase reactant in reactions
of inﬂammation, but also as an immunological, vascular,
and extravascular regulator of health and disease.
Indeed, a fundamental biochemical axiom states that
protein functions can be regulated by distinct
structures.
MATERIALS AND METHODS
Recombinant CRP (rmCRP) genetic engineering,
expression, and collection as inclusion bodies
CRP is a non-glycosylated protein of ﬁve identical sub-
units, each with a molecular weight of 23 kD and con-
taining one intrachain disulﬁde bond, arranged in a
cyclic discoid structure. Genomic and cDNA clones
coding for the human CRP subunit have been isolated
(Lei et al. 1985; Woo et al. 1985), and the corresponding
protein amino acid sequence has been assigned. The
original CRP cDNA clone was isolated from a human
liver library and was the kind gift of Drs. Harvey Colton
& Bruce Dowton of Harvard University. A number of
modiﬁcation and site-directed mutagenesis procedures
were performed on this clone to replace and substitute
selected nucleotides for improved, unambiguous
expression in E. coli, improved plasmid stability,
decreased basal transcription, and increased induced
expression levels (Reznikoff and Gold 1986). Most
speciﬁcally, the genetically engineered recombinant CRP
subunit (rmCRP) was manipulated to purposefully differ
from the biological CRP subunit at three residue posi-
tions: (1) the N-terminal pyroglutamic amino acid of
biological CRP was changed to glutamine and was pre-
ceded by a formylated-methionine residue; (2) cysteine
residue 36 was substituted with an alanine residue
(C36A); and (3) cysteine residue 97 was substituted
with an alanine residue (C97A) (collectively known as
cys-mutated rmCRP) (Potempa et al. 1999).
The Cys-mutated rmCRP gene was cloned into the T7
RNA polymerase expression system under the lacUV5
promoter (Tabor and Richardson 1985), and trans-
formed into E. coli BLR(DE3). Transformed bacteria were
expanded prior to induction of the rmCRP gene with
Isopropyl b-D-1-thiogalactopyranoside (IPTG). Induced
cells were harvested using continuous ﬂow centrifuga-
tion, washed, and suspended in 20 mmol/L Tris HCl, pH
7.6, containing 5 mmol/L EDTA and 1 mmol/L phenyl-
methylsulfonylﬂuoride (PMSF) (i.e., ‘‘Breakage buffer’’)
and passed twice through a homogenizer at a pressure of
500 bar. E. coil cell pellets were collected, resuspend in
buffers, and repassed through the homogenizer at
700 bars. The collected materials were labeled as
recombinant mutant CRP subunit Inclusion Bodies
(rmCR-IBs) and store at below -20 C until processed.
The plasmid containing the CRP gene pX(T7) CRP13
was isolated from the expression strain and puriﬁed on
a cesium chloride gradient. The CRP coding region was
sequenced by the method of Sanger (Sanger et al. 1977)
using 33P-dATP and conﬁrmed except for the genetically
engineered changes factored into the sequence. No base
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additions, deletions, or substitutions were unintention-
ally introduced into the sequence.
Solubilization of inclusion bodies with anhydride
reagents
Citraconic anhydride, maleic anhydride, succinic anhy-
dride, and guanidinium HCl were purchased from
Sigma-Aldrich, St. Louis, MO, USA. Phenyl Sepharose
(high substitution) and DEAE Sepharose fast ﬂow
chromatography resins were purchased from GE
Healthcare Life Sciences, Piscataway, NJ, USA. All buffer
reagents were analytical grade or better and were
purchased from Sigma-Aldrich, VWR (Radnor, PA) or
Bio-Rad Laboratories (Hercules, CA).
Chemical modiﬁcation reactions with anhydride
reagents were carried out with slight modiﬁcations as
described in Means and Feeney (Means and Feeney
1971) and Wong (Wong 2000). Generally, protein sus-
pensions were maintained in 0.1 N Na Bicarbonate
buffer at pH 9.0 and small amounts of anhydride
reagent (either liquid aliquots with citraconic anhydride
or solid crystals for maleic anhydride or succinic
anhydride) were added to moderately stirred protein at
room temperature. The pH of the mixture was moni-
tored continuously, and drops of NaOH (1 N or 5 N)
were added to stabilize and maintain the pH at 9.0.
When the pH change was observed to slow or stop,
fresh anhydride reagent was added and the process
repeated for 5-to-10 cycles. To estimate the level of
substitution with maleylation or citraconylation, the
change in absorbance at 250 nm was measured, and the
moles of substitution per mole of CRP subunit were
calculated using an extinction coefﬁcient of e = 3360
(mol/L)-1 cm-1 (Means and Feeney 1971). Most gen-
erally, between 4 and 10 mol of acyl group were
quantiﬁed for each mole of CRP subunit. Of note, there
are 13 lysine residues (the primary site for the acylation
reaction with anhydride reagents) in each CRP subunit
(Lei et al. 1985; Woo et al. 1985; Thompson et al. 1999).
Part, but not all protein solubilized. The mixture was
centrifuged at 30009g at 4 C for 30 min, and the sol-
uble fraction was separated from the still precipitated
protein. The citraconic-solubilized inclusion body (in
bicarbonate) was directly processed on Phenyl Sephar-
ose hydrophobic adsorption chromatography resin (see
below). The collected precipitated protein was resus-
pended in 0.1 N NaHCO3 and was brieﬂy exposed to
pH[ 12.0 by addition of 5 N NaOH. After the protein
suspension clariﬁed, the sample was quickly returned to
pH values of *8.5 for separate, but identical processing
on Phenyl Sepharose.
Decitraconylation
When desired, citraconylated protein was decitracony-
lated by dialyzing puriﬁed protein in 0.05 mol/L Citrate
(pH 3.5) at room temperature for 2 h. Resultant rmCRP
was insoluble. Maleic groups may also be removed
modiﬁed protein by acid dialysis. However, removal of
maleyl group is incomplete under the described condi-
tions so that use of the 2-methyl maleic anhydride
derivative (citraconic anhydride) is the preferred
method used herein.
In all puriﬁcation and processing steps, protein con-
centrations were determined using a BCA assay (Ther-
moScientiﬁc, Waltham, MA) and by absorbance at
280 nm using Beer’s Law, and a CRP extinction coefﬁ-
cient of 1.95 mg/mL or 44,740 (mol/L)-1 cm-1.
In the analytical evaluation of various protein sam-
ples, Serum Protein Electrophoresis was performed
using the Beckman Paragon SPE Gel Electrophoresis
System using a precast 1 % Agarose Gel with a barbital
running buffer.
Electron microscopy (EM)
CRP protein samples were diluted to 50*100 lg/mL
and observed by negatively stained electron microscopy
(Zhu et al. 2011). In brief, 2 lL droplet of sample was
added to a freshly glow-discharged carbon-coated
300-mesh copper EM grid for 10 s followed by staining
with 1 % phosphotungstic acid (PTA) for 60 s. The grids
were observed in a Tecnai G20 (FEI) 200 kV EM.
Assay for endotoxin
Protein batches were assayed for endotoxin contami-
nant by Limulus assay (Sigma, St. Louis, MO, USA)
according to the instruction. Additional puriﬁcation step
through Detoxi-Gel Columns (Pierce, Rockford, IL, USA)
was performed to remove endotoxin when necessary.
The ﬁnal endotoxin level of all protein solutions was
below the detection limit 0.06 EU/mL of the assay.
ELISA analysis for screening monoclonal
and polyclonal anti-CRP reagents
Ninety-six well polystyrene microtiter plates were
coated with various concentrations of protein, dissolved
in 0.1 mol/L Na bicarbonate (pH 9.0). Most routinely,
0.2 lg of protein was coated per well, but for quanti-
tative comparisons of relative speciﬁcity of polyclonal
reagents for each of native and mCRP, the primary coat
protein was varied from 0.001 lg/well to 0.8 lg/well.
Because direct coating of the native CRP pentamer onto
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the polystyrene plate surface results in a loss of native
CRP antigenicity, the native protein required calcium-
dependent capture to a surface immobilized protein
carrier (Keyhole Lympet Hemocyanin (KLH) derivitized
with native CRP’s primary ligand –phopshorylcholine
(PC) (i.e., PC-KLH).
After backcoating, mouse monoclonal anti-pCRP
clone 1D6 or mouse monoclonal anti-mCRP clone 3H12
(Ying et al. 1989, 1992) was added, and bound antibody
was detected with goat a-mouse IgG (whole mole-
cule)—peroxidase (Sigma-Aldrich, St Louis, MO) and
2,20-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid
(ABTS) color reagent.
In experiments using polyclonal reagents, pCRP or
mCRP antigens were immobilized as described and anti-
human CRP—IgG Fraction of Antiserum produced in
rabbit (Sigma-Aldrich product C3527—lot 11K9175)
was added at various dilutions to immobilized antigens.
Bound rabbit antibody was detected with anti-rabbit
IgG (whole molecule, developed in goat)-peroxidase
conjugate (Sigma-Aldrich Product No. A6667—lot
103K9167) and ABTS color reagent.
The level of reactivity of various dilutions of poly-
clonal antiserum to normalized levels of protein anti-
gens (0.001 lg/well to 0.8 lg/well) was plotted, and
least-squares analysis was used to establish trendlines
which were used to compare dilutions needed to detect
equivalent reactivity for native and mCRP antigens.
Abbreviations
CRP (C-reactive protein)
mCRP Modiﬁed, monomeric C-reactive protein
isoform produced when the CRP protein
pentamer is dissociated
rmCRP A genetically engineered recombinant
analog of mCRP expressed in E. coli




ELISA Enzyme linked immunosorbent assay
GuHCl Guanidinium Hydrochloride
mAb Monoclonal antibody
PC-KLH Keyhole limpet hemocyanin substituted
with phosphoryl choline ligands
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel
electrophoresis
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